Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.46 USD | -3.52% | -4.69% | +34.01% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.01% | 273M | |
+3.30% | 43.84B | |
+8.48% | 41.68B | |
+45.55% | 41.25B | |
-10.92% | 27.04B | |
+9.48% | 25.53B | |
-25.56% | 18.18B | |
+0.38% | 12.29B | |
+28.69% | 12.29B | |
+6.89% | 11.15B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Transcript : Enanta Pharmaceuticals, Inc., Q3 2022 Earnings Call, Aug 08, 2022